MASS vs. INMB, JYNT, CRDF, VERU, ATOS, OMER, AKYA, ALIM, PROF, and ABOS
Should you be buying 908 Devices stock or one of its competitors? The main competitors of 908 Devices include INmune Bio (INMB), Joint (JYNT), Cardiff Oncology (CRDF), Veru (VERU), Atossa Therapeutics (ATOS), Omeros (OMER), Akoya Biosciences (AKYA), Alimera Sciences (ALIM), Profound Medical (PROF), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "medical" sector.
INmune Bio (NASDAQ:INMB) and 908 Devices (NASDAQ:MASS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, community ranking, profitability, earnings and risk.
12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 88.1% of 908 Devices shares are owned by institutional investors. 36.1% of INmune Bio shares are owned by insiders. Comparatively, 27.8% of 908 Devices shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
INmune Bio has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500. Comparatively, 908 Devices has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.
INmune Bio presently has a consensus target price of $16.00, suggesting a potential upside of 47.60%. 908 Devices has a consensus target price of $14.00, suggesting a potential upside of 151.80%. Given INmune Bio's higher probable upside, analysts plainly believe 908 Devices is more favorable than INmune Bio.
In the previous week, INmune Bio had 3 more articles in the media than 908 Devices. MarketBeat recorded 6 mentions for INmune Bio and 3 mentions for 908 Devices. 908 Devices' average media sentiment score of 0.09 beat INmune Bio's score of -0.44 indicating that INmune Bio is being referred to more favorably in the media.
INmune Bio has higher earnings, but lower revenue than 908 Devices. INmune Bio is trading at a lower price-to-earnings ratio than 908 Devices, indicating that it is currently the more affordable of the two stocks.
908 Devices has a net margin of -72.47% compared to 908 Devices' net margin of -19,360.00%. INmune Bio's return on equity of -21.09% beat 908 Devices' return on equity.
INmune Bio received 122 more outperform votes than 908 Devices when rated by MarketBeat users. Likewise, 75.69% of users gave INmune Bio an outperform vote while only 60.00% of users gave 908 Devices an outperform vote.
Summary
INmune Bio and 908 Devices tied by winning 8 of the 16 factors compared between the two stocks.
Get 908 Devices News Delivered to You Automatically
Sign up to receive the latest news and ratings for MASS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MASS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
908 Devices Competitors List
Related Companies and Tools
